U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C9H14N2.ClH
Molecular Weight 186.682
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PHENIPRAZINE HYDROCHLORIDE

SMILES

Cl.CC(CNN)C1=CC=CC=C1

InChI

InChIKey=VATMJXRAQUGDSQ-UHFFFAOYSA-N
InChI=1S/C9H14N2.ClH/c1-8(7-11-10)9-5-3-2-4-6-9;/h2-6,8,11H,7,10H2,1H3;1H

HIDE SMILES / InChI
PHENIPRAZINE is a monoamine oxidase inhibitor of the hydrazine chemical class that was used for the treatment of depression, schizophrenia, and also as a long-acting coronary vasodilator in patients suffering from angina pectoris. PHENIPRAZINE was discontinued due to toxicity concerns such as jaundice, amblyopia, and optic neuritis.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Catron

Approved Use

Unknown
Primary
Catron

Approved Use

Unknown
Doses

Doses

DosePopulationAdverse events​
9 mg 1 times / day multiple, oral
Recommended
Dose: 9 mg, 1 times / day
Route: oral
Route: multiple
Dose: 9 mg, 1 times / day
Sources:
unhealthy, 50
n = 1
Health Status: unhealthy
Condition: Depression
Age Group: 50
Sex: M
Population Size: 1
Sources:
Disc. AE: Amblyopia...
AEs leading to
discontinuation/dose reduction:
Amblyopia
Sources:
18 mg 1 times / day multiple, oral (max)
Studied dose
Dose: 18 mg, 1 times / day
Route: oral
Route: multiple
Dose: 18 mg, 1 times / day
Sources: Page: p.1959
unhealthy, 65
n = 1
Health Status: unhealthy
Condition: Hypertension
Age Group: 65
Sex: F
Population Size: 1
Sources: Page: p.1959
Disc. AE: Hepatotoxicity...
AEs leading to
discontinuation/dose reduction:
Hepatotoxicity (grade 5)
Sources: Page: p.1959
25 mg 1 times / day multiple, oral
Highest studied dose
Dose: 25 mg, 1 times / day
Route: oral
Route: multiple
Dose: 25 mg, 1 times / day
Sources: Page: p.2
unhealthy
n = 1
Health Status: unhealthy
Condition: Depression
Population Size: 1
Sources: Page: p.2
Disc. AE: Blurred vision, Scotoma...
AEs leading to
discontinuation/dose reduction:
Blurred vision
Scotoma
Ataxia
Weakness in extremity
Sources: Page: p.2
25 mg 1 times / day multiple, oral
Highest studied dose
Dose: 25 mg, 1 times / day
Route: oral
Route: multiple
Dose: 25 mg, 1 times / day
Sources: Page: p.2
unhealthy
n = 1
Health Status: unhealthy
Condition: Depression
Population Size: 1
Sources: Page: p.2
Disc. AE: Maculo-papular rash, Blurred vision...
AEs leading to
discontinuation/dose reduction:
Maculo-papular rash
Blurred vision
Sources: Page: p.2
AEs

AEs

AESignificanceDosePopulation
Amblyopia Disc. AE
9 mg 1 times / day multiple, oral
Recommended
Dose: 9 mg, 1 times / day
Route: oral
Route: multiple
Dose: 9 mg, 1 times / day
Sources:
unhealthy, 50
n = 1
Health Status: unhealthy
Condition: Depression
Age Group: 50
Sex: M
Population Size: 1
Sources:
Hepatotoxicity grade 5
Disc. AE
18 mg 1 times / day multiple, oral (max)
Studied dose
Dose: 18 mg, 1 times / day
Route: oral
Route: multiple
Dose: 18 mg, 1 times / day
Sources: Page: p.1959
unhealthy, 65
n = 1
Health Status: unhealthy
Condition: Hypertension
Age Group: 65
Sex: F
Population Size: 1
Sources: Page: p.1959
Ataxia Disc. AE
25 mg 1 times / day multiple, oral
Highest studied dose
Dose: 25 mg, 1 times / day
Route: oral
Route: multiple
Dose: 25 mg, 1 times / day
Sources: Page: p.2
unhealthy
n = 1
Health Status: unhealthy
Condition: Depression
Population Size: 1
Sources: Page: p.2
Blurred vision Disc. AE
25 mg 1 times / day multiple, oral
Highest studied dose
Dose: 25 mg, 1 times / day
Route: oral
Route: multiple
Dose: 25 mg, 1 times / day
Sources: Page: p.2
unhealthy
n = 1
Health Status: unhealthy
Condition: Depression
Population Size: 1
Sources: Page: p.2
Scotoma Disc. AE
25 mg 1 times / day multiple, oral
Highest studied dose
Dose: 25 mg, 1 times / day
Route: oral
Route: multiple
Dose: 25 mg, 1 times / day
Sources: Page: p.2
unhealthy
n = 1
Health Status: unhealthy
Condition: Depression
Population Size: 1
Sources: Page: p.2
Weakness in extremity Disc. AE
25 mg 1 times / day multiple, oral
Highest studied dose
Dose: 25 mg, 1 times / day
Route: oral
Route: multiple
Dose: 25 mg, 1 times / day
Sources: Page: p.2
unhealthy
n = 1
Health Status: unhealthy
Condition: Depression
Population Size: 1
Sources: Page: p.2
Blurred vision Disc. AE
25 mg 1 times / day multiple, oral
Highest studied dose
Dose: 25 mg, 1 times / day
Route: oral
Route: multiple
Dose: 25 mg, 1 times / day
Sources: Page: p.2
unhealthy
n = 1
Health Status: unhealthy
Condition: Depression
Population Size: 1
Sources: Page: p.2
Maculo-papular rash Disc. AE
25 mg 1 times / day multiple, oral
Highest studied dose
Dose: 25 mg, 1 times / day
Route: oral
Route: multiple
Dose: 25 mg, 1 times / day
Sources: Page: p.2
unhealthy
n = 1
Health Status: unhealthy
Condition: Depression
Population Size: 1
Sources: Page: p.2
PubMed

PubMed

TitleDatePubMed
Toxic liver injuries.
1973 Aug
Name Type Language
PHENIPRAZINE HYDROCHLORIDE
Common Name English
JB-516
Code English
CATRONIAZID
Brand Name English
CAVODIL
Brand Name English
NSC-78085
Code English
CATRON
Brand Name English
CATRAL
Brand Name English
PHENIPRAZINE DL-FORM HYDROCHLORIDE [MI]
Common Name English
NSC-17766
Code English
CATRON HYDROCHLORIDE
Brand Name English
PHENIPRAZINE HCL
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C667
Created by admin on Fri Dec 15 16:26:50 GMT 2023 , Edited by admin on Fri Dec 15 16:26:50 GMT 2023
Code System Code Type Description
MERCK INDEX
m882
Created by admin on Fri Dec 15 16:26:50 GMT 2023 , Edited by admin on Fri Dec 15 16:26:50 GMT 2023
PRIMARY Merck Index
DRUG BANK
DBSALT001273
Created by admin on Fri Dec 15 16:26:50 GMT 2023 , Edited by admin on Fri Dec 15 16:26:50 GMT 2023
PRIMARY
ChEMBL
CHEMBL22498
Created by admin on Fri Dec 15 16:26:50 GMT 2023 , Edited by admin on Fri Dec 15 16:26:50 GMT 2023
PRIMARY
NSC
78085
Created by admin on Fri Dec 15 16:26:50 GMT 2023 , Edited by admin on Fri Dec 15 16:26:50 GMT 2023
PRIMARY
CAS
54779-57-6
Created by admin on Fri Dec 15 16:26:50 GMT 2023 , Edited by admin on Fri Dec 15 16:26:50 GMT 2023
SUPERSEDED
FDA UNII
5B3OM8452C
Created by admin on Fri Dec 15 16:26:50 GMT 2023 , Edited by admin on Fri Dec 15 16:26:50 GMT 2023
PRIMARY
CAS
15573-15-6
Created by admin on Fri Dec 15 16:26:50 GMT 2023 , Edited by admin on Fri Dec 15 16:26:50 GMT 2023
NON-SPECIFIC STOICHIOMETRY
NCI_THESAURUS
C73612
Created by admin on Fri Dec 15 16:26:50 GMT 2023 , Edited by admin on Fri Dec 15 16:26:50 GMT 2023
PRIMARY
NSC
17766
Created by admin on Fri Dec 15 16:26:50 GMT 2023 , Edited by admin on Fri Dec 15 16:26:50 GMT 2023
PRIMARY
PUBCHEM
6182
Created by admin on Fri Dec 15 16:26:50 GMT 2023 , Edited by admin on Fri Dec 15 16:26:50 GMT 2023
PRIMARY
CAS
66-05-7
Created by admin on Fri Dec 15 16:26:50 GMT 2023 , Edited by admin on Fri Dec 15 16:26:50 GMT 2023
PRIMARY
EPA CompTox
DTXSID8021149
Created by admin on Fri Dec 15 16:26:50 GMT 2023 , Edited by admin on Fri Dec 15 16:26:50 GMT 2023
PRIMARY